Ranibizumab reduces leakage after macular telangiectasia, offers modest BCVA improvement
Although ranibizumab injections helped reduce leakage secondary to macular telangiectasia type 2, improvements in best corrected visual acuity were similar to those seen in the untreated fellow eye, according to study findings.
The study included 10 eyes of 10 patients with bilateral macular telangiectasia without subretinal neovascularization. Eyes were randomly assigned to injection with 0.3 mg Lucentis (ranibizumab, Genentech) or 0.5 mg ranibizumab in only one eye. Injections were given at baseline, 1 month and 2 months; additional injections at months 3, 4 and 5 were given at the discretion of the researchers. Median number of injections given was six.
Follow-up occurred through 6 months, during which time the researchers evaluated BCVA, ﬂuorescein angiography and optical coherence tomography.
At 3 months, the median change in BCVA was four letters for both dosage groups and three letters in the untreated fellow eye. Retinal leakage decreased 0.87 disk area in the 0.3 mg ranibizumab group and 0.76 disk area in the 0.5 mg ranibizumab group, according to the researchers. Additionally, mean change in central subfield retinal thickness was 1 µm in the 0.3 mg ranibizumab group and −11 µm in the 0.5 mg ranibizumab group.
Disclosure: See the study for full list of all authors’ relevant financial disclosures.